Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Inflammation and oncogenesis: a vicious connection.

Grivennikov SI, Karin M.

Curr Opin Genet Dev. 2010 Feb;20(1):65-71. doi: 10.1016/j.gde.2009.11.004. Epub 2009 Dec 25. Review.

2.

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.

Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL.

J Immunol. 2009 Aug 15;183(4):2475-83. doi: 10.4049/jimmunol.0900986. Epub 2009 Jul 27.

3.

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.

Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH.

Blood. 2009 Jun 11;113(24):6102-11. doi: 10.1182/blood-2008-12-195354. Epub 2009 Apr 14.

4.

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.

5.

BAR the door: cancer suppression by amphiphysin-like genes.

Prendergast GC, Muller AJ, Ramalingam A, Chang MY.

Biochim Biophys Acta. 2009 Jan;1795(1):25-36. doi: 10.1016/j.bbcan.2008.09.001. Epub 2008 Sep 18. Review.

6.

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Katz JB, Muller AJ, Prendergast GC.

Immunol Rev. 2008 Apr;222:206-21. doi: 10.1111/j.1600-065X.2008.00610.x. Review.

PMID:
18364004
7.

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ.

J Med Chem. 2008 Mar 27;51(6):1706-18. doi: 10.1021/jm7014155. Epub 2008 Mar 5. Erratum in: J Med Chem. 2008 Nov 27;51(22):7325.

8.

Immune escape as a fundamental trait of cancer: focus on IDO.

Prendergast GC.

Oncogene. 2008 Jun 26;27(28):3889-900. doi: 10.1038/onc.2008.35. Epub 2008 Mar 3. Review.

PMID:
18317452
9.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
10.

Adaptive immunity maintains occult cancer in an equilibrium state.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD.

Nature. 2007 Dec 6;450(7171):903-7. Epub 2007 Nov 18.

PMID:
18026089
11.

The adaptive immune response to sporadic cancer.

Willimsky G, Blankenstein T.

Immunol Rev. 2007 Dec;220:102-12. Review.

PMID:
17979842
12.

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Gajewski TF.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61. Review.

13.

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH.

J Clin Invest. 2007 Sep;117(9):2570-82.

14.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

15.

Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Munn DH, Mellor AL.

J Clin Invest. 2007 May;117(5):1147-54. Review.

16.

Cancer immunologists and cancer biologists: why we didn't talk then but need to now.

Prendergast GC, Jaffee EM.

Cancer Res. 2007 Apr 15;67(8):3500-4. Epub 2007 Apr 5.

17.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

18.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H.

J Exp Med. 2007 Jan 22;204(1):49-55. Epub 2007 Jan 8.

19.

The tumor-draining lymph node as an immune-privileged site.

Munn DH, Mellor AL.

Immunol Rev. 2006 Oct;213:146-58. Review.

PMID:
16972902
20.

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

Muller AJ, Scherle PA.

Nat Rev Cancer. 2006 Aug;6(8):613-25. Review. Erratum in: Nat Rev Cancer. 2006 Sep;6(9):742.

PMID:
16862192

Supplemental Content

Support Center